29TA Stock Chart & Stats
€1.87
-€0.02(-1.14%)
At close: 4:00 PM EDT
€1.87
-€0.02(-1.14%)
Day’s Range― - ―
52-Week Range€0.99 - €2.30
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€18.60M
Enterprise Value€22.10M
Total Cash (Recent Filing)€9.19M
Total Debt (Recent Filing)€5.56M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding11,574,362
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.70
Price to Sales (P/S)6.24
P/FCF Ratio7.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€8.28M
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationPositive operating and free cash flow mark a meaningful recovery from deeply negative operating cash flow in 2023. This improves the company’s ability to fund ongoing obligations and preserve strategic flexibility, although the durability of the improvement still depends on stabilizing the underlying business.
Modest LeverageLow and improving leverage provides a more stable financial foundation than the company had during earlier periods of negative equity. Modest debt relative to equity can reduce solvency pressure and leave management more flexibility while it manages weak operating profitability and evaluates future strategic options.
Lean Royalty-Focused ModelThe shift toward royalty collection reduces the company’s reliance on maintaining a traditional women’s-healthcare development and commercialization operation. Retaining rights to existing licensed products gives the business an asset-based model that can generate revenue without rebuilding a fully integrated commercial platform.
Bears Say
Declining Revenue BaseA small and declining revenue base limits operating scale and makes the company more exposed to changes in licensed-product sales. Without sustained top-line growth, fixed corporate costs remain difficult to absorb and the royalty-focused model may not produce dependable earnings over the next several quarters.
Negative Operating ProfitabilityPersistent operating and EBITDA losses show that the current revenue base still does not support the company’s cost structure. This weakens the quality of the recent recovery because near-breakeven net results have not yet translated into consistent operating profitability or demonstrated earnings durability.
Strategic UncertaintyThe strategic alternatives review creates uncertainty around the company’s future structure, asset ownership and operating direction. A transaction may eventually unlock value, but the absence of a timetable or certainty can delay strategic execution and makes the longer-term royalty-focused plan less predictable.
TherapeuticsMD News
29TA FAQ
What was TherapeuticsMD’s price range in the past 12 months?
TherapeuticsMD lowest stock price was €0.99 and its highest was €2.30 in the past 12 months.
What is TherapeuticsMD’s market cap?
TherapeuticsMD’s market cap is €18.60M.
When is TherapeuticsMD’s upcoming earnings report date?
TherapeuticsMD’s upcoming earnings report date is Nov 17, 2026 which is in 23 days.
How were TherapeuticsMD’s earnings last quarter?
TherapeuticsMD released its earnings results on Aug 11, 2026. The company reported €0.011 earnings per share for the quarter.
Is TherapeuticsMD overvalued?
According to Wall Street analysts TherapeuticsMD’s price is currently Overvalued.
Does TherapeuticsMD pay dividends?
TherapeuticsMD does not currently pay dividends.
What is TherapeuticsMD’s EPS estimate?
TherapeuticsMD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TherapeuticsMD have?
TherapeuticsMD has 11,574,362 shares outstanding.
What happened to TherapeuticsMD’s price movement after its last earnings report?
TherapeuticsMD reported an EPS of €0.011 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of TherapeuticsMD?
Currently, no hedge funds are holding shares in DE:29TA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TherapeuticsMD
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.